AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

AC Immune S.A.NASDAQ: ACIU

Capital Expenditures · Q4 FY2025 · quarter ended Dec 2025

Capital expenditures grows, but more slowly than its trailing trend

Q4 FY2025 capital expenditures of CHF 107.16K (cash outflow) rose 19.1% year over year, behind the +56.3% change in trailing-twelve-month capital expenditures. Sequentially, it rose 84.8% from the prior quarter. Over 3 fiscal years it compounded at -11.5% a year.

Context

  • Capital expenditures amounted to 24.1% of revenue in FY2025, up 21.9 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +19.1% toward the trailing-twelve-month pace of +56.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-CHF 107.16K+84.8% QoQ
Last fiscal yearDec 2025
-CHF 859.54K+49.2% YoY
LTMDec 2025
-CHF 900.16K+56.3% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+19.1%——
1 year+49.2%——
3-year CAGR-11.5%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

CHF · from the cash flow

Latest · FY2025
(859.54K) CHF
Year-over-year change
-49.2%

Capital Expenditures vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +56.3% is the 2nd highest of 8, against a peer median of -29.2%.
  • Capital expenditures amounts to 25.2% of revenue for ACIU, versus a peer median of 7.8%.
ACIU Competitors
Capital Expenditures for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026$16.69M USD+140168207.3%—7.8%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$6.08M USD—+88.7%—
CLLSCellectis S.A.LTM Mar 2026$2.23M USD-44.0%-1.0%3.3%
ACIUAC Immune S.A.LTM Dec 2025CHF 900.16K CHF+56.3%-11.5%25.2%
LYELLyell Immunopharma, Inc.LTM Mar 2026$623K USD-8.4%-68.2%2009.7%
ANROAlto Neuroscience, Inc.LTM Mar 2026$556K USD-70.3%-68.0%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$496K USD+19.8%+25.1%—
SLNSilence Therapeutics plcLTM Mar 2026$106K USD—-53.4%11.5%
ANNXAnnexon, Inc.LTM Mar 2026$63K USD-29.2%-72.4%—
MREOMereo BioPharma Group plcLTM Mar 2026$1.52K USD-99.5%+15.4%0.3%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$4 USD———
Peer median (excluding ACIU) —-29.2%-27.2%7.8%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73M)(70.75M)(54.23M)(50.92M)(67.28M)
Depreciation & Amortization2.41M2.36M2.22M2.16M2.39M
Deferred Income Tax130K0000
Stock-Based Compensation4.13M3.33M4.37M5.47M0
Change in Working Capital6.84M(8.43M)(15.16M)107.51M(6.47M)
Accounts Receivables(99K)603K(14.8M)13.55M877.68K
Inventory00000
Accounts Payables0000(565.39K)
Other Working Capital6.94M(9.04M)(360K)93.96M(6.78M)
Other Non-Cash Items(6.2M)(72K)2.41M1.61M5.21M
Operating Cash Flow(65.69M)(73.57M)(60.41M)65.84M(66.15M)
Capital Expenditures(2.64M)(1.24M)(801K)(576K)(859.54K)
Acquisitions (Net)000014.33K
Purchases of Investments00000
Sales of Investments000061.69M
Other Investing Activities(51.03M)25M66.45M(104.71M)(162.36K)
Investing Cash Flow(53.66M)23.76M65.65M(105.29M)60.69M
Debt Repayment22.95M(569K)(548K)(683K)(1.03M)
Common Stock Issued17.8M7K43.8M111K5.73K
Common Stock Repurchased0(8K)000
Dividends Paid00000
Other Financing Activities(6K)(776K)0(548K)46.13K
Financing Cash Flow40.75M(1.35M)43.25M(1.12M)(974.14K)
Effect of Forex Changes(70K)521K(1.58M)(1.65M)1.51M
Net Change in Cash(78.68M)(50.63M)46.91M(42.22M)(4.92M)
Free Cash Flow(68.32M)(74.81M)(61.21M)65.27M(67.01M)

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.